Loading
Radiation oncologist who built AI models from trial slides to decide which prostate cancer patients need hormone therapy.
Daniel Spratt led the development and validation of the ArteraAI multimodal AI prostate test using digitised pathology and clinical data from NRG/RTOG trials, the first AI biomarker to enter NCCN prostate guidelines. He has led analyses of the Decipher genomic classifier and chairs NRG GU trials of biomarker-guided treatment intensification and de-intensification.
| Title | Journal | Year |
|---|---|---|
| Artificial intelligence predictive model for hormone therapy use in prostate cancer | NEJM Evidence | 2023 |
| Individual patient-level meta-analysis of the performance of the Decipher genomic classifier in high-risk men after prostatectomy to predict development of metastatic disease | JCO | 2017 |
Shares IMRT / IGRT (modern external beam), Prostate cancer and the tags prostate, radiotherapy.
Shares IMRT / IGRT (modern external beam), Prostate cancer and the tags prostate, radiotherapy.
Shares Prostate cancer and the tags prostate, radiotherapy.
Shares Prostate cancer and the tags prostate, radiotherapy.
Shares ArteraAI Prostate, Digital pathology & AI, Prostate cancer.
Shares Prostate cancer and the tags prostate, radiotherapy.
Shares Digital pathology & AI, Prostate cancer and the tag ai.
Shares ArteraAI Prostate, Digital pathology & AI, Prostate cancer.